Browse CD80

Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation. ; FUNCTION: (Microbial infection) Acts as a receptor for adenovirus subgroup B.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002825 regulation of T-helper 1 type immune response
GO:0002827 positive regulation of T-helper 1 type immune response
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0007159 leukocyte cell-cell adhesion
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019058 viral life cycle
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030258 lipid modification
GO:0030260 entry into host cell
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0032496 response to lipopolysaccharide
GO:0032604 granulocyte macrophage colony-stimulating factor production
GO:0032623 interleukin-2 production
GO:0032645 regulation of granulocyte macrophage colony-stimulating factor production
GO:0032663 regulation of interleukin-2 production
GO:0032725 positive regulation of granulocyte macrophage colony-stimulating factor production
GO:0032743 positive regulation of interleukin-2 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0042035 regulation of cytokine biosynthetic process
GO:0042088 T-helper 1 type immune response
GO:0042089 cytokine biosynthetic process
GO:0042093 T-helper cell differentiation
GO:0042094 interleukin-2 biosynthetic process
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042253 granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation
GO:0044409 entry into host
GO:0045063 T-helper 1 cell differentiation
GO:0045076 regulation of interleukin-2 biosynthetic process
GO:0045086 positive regulation of interleukin-2 biosynthetic process
GO:0045423 regulation of granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0045425 positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045624 positive regulation of T-helper cell differentiation
GO:0045625 regulation of T-helper 1 cell differentiation
GO:0045627 positive regulation of T-helper 1 cell differentiation
GO:0045785 positive regulation of cell adhesion
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046641 positive regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0046718 viral entry into host cell
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
Molecular Function GO:0001618 virus receptor activity
GO:0015026 coreceptor activity
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
GO:0098636 protein complex involved in cell adhesion
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04620 Toll-like receptor signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-389356: CD28 co-stimulation
R-HSA-389357: CD28 dependent PI3K/Akt signaling
R-HSA-389359: CD28 dependent Vav1 pathway
R-HSA-389513: CTLA4 inhibitory signaling
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-180292: GAB1 signalosome
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD80 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD80 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28280249Lung CarcinomaPromote immunity (T cell function); Essential for immunotherapyHere, we demonstrate that the CD28/B7 costimulatory pathway is essential for effective PD-1 therapy during chronic viral infection. Conditional gene deletion showed a cell-intrinsic requirement of CD28 for CD8 T cell proliferation after PD-1 blockade. B7-costimulation was also necessary for effective PD-1 therapy in tumor-bearing mice. In addition, we found that CD8 T cells proliferating in blood after PD-1 therapy of lung cancer patients were predominantly CD28-positive.
29341428Aldefluor+ Breast CarcinomaPromote immunity (T cell function)Gene expression analysis of the sorted tumor cells revealed that the Aldefluor+ tumor cells has decreased expression of transporter associated with antigen processing (TAP) genes and co-stimulatory molecule CD80, which would decrease susceptibility to T cells.
24523507T-Cell Non-Hodgkin LymphomaInhibit immunityCutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. Coculture of CTCL cells with normal T lymphocytes consisting of both CD4(+) and CD8(+) populations or the CD4(+) subset alone, transfected with CD152 mRNA, inhibits proliferation of normal T cells in a CD152- and CD80-dependent manner. These data identify a new mechanism of immune evasion in CTCL and suggest that the CD80-CD152 axis may become a therapeutic target in this type of lymphoma.
16424052Breast carcinomaPromote immunity (T cell function); essential for immunotherapyTumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. To determine if Ii expression affects presentation of MHC class II-restricted endogenously synthesized tumor antigens in human tumor cells, HLA-DR-MCF10 breast cancer cells were transduced with the CIITA, CD80 costimulatory molecule gene, and with or without small interfering RNAs (siRNA) specific for Ii.
22392913Melanoma; Breast CarcinomaPromote immunity (T cell function); essential for immunotherapyLaser illumination also slightly but significantly enhanced the expression of costimulatory molecule CD80 and MHC I on inoculated DCs. As a result, more vigorous expansion of tumor-specific IFN-γ(+)CD8(+) T lymphocytes and enhanced CTL activity against 4T1 but not irrelevant tumor cells were obtained in the laser-treated group over the control group.
24819296MelanomaPromote immunityUsing T cells from CD28-deficient mice and antibodies to block CD28 on human T cells, we now report that a soluble form of CD80 mediates this effect by simultaneously neutralizing PD-1-PD-L1-mediated immunosuppression and by providing CD80-CD28 costimulation, and is more effective than antibodies to PD-L1 or PD-1 in maintaining IFNγ production by PD-1(+) activated T cells. Therefore, soluble CD80 may be a more effective therapeutic than these checkpoint antibodies for facilitating the development and maintenance of antitumor immunity because it has the dual functions of preventing PD-L1-mediated immunosuppression and simultaneously delivering the second signal for T-cell activation.
19188167Colon AdenocarcinomaInhibit immunityHere, we showed that short-term administration of anti-B7-1/B7-2 monoclonal antibodies in TRAMP mice leads to significant inhibited primary tumor growth and the size of metastatic lesions. The treatment is effective to inhibit MC38 colon cancer growth. Correspondingly, this treatment results in a transient reduction of Treg in both thymus and the periphery. In vivo cytotoxicity assay revealed T antigen-specific CTL effectors in anti-B7-treated but not control IgG-treated TRAMP mice.
19109206LeukemiaPromote immunity (T cell function)Both CD70 and CD80/CD86 up-regulated on CD40-stimulated blasts contribute to primary stimulation of T cell proliferation and cytokine production in an additive manner. These two signals also cooperate in the prevention of T cell anergy. In contrast to blockade of CD70 during the effector phase, inhibition of CD70-mediated costimulation during generation of antileukemic T cells prevents effector cell proliferation and reduces their cytotoxic capacity.
20100959Intermediate Atypical Prostate CarcinomaPromote immunityPROSTVAC-VF comprises two recombinant viral vectors, each encoding transgenes for PSA, and three immune costimulatory molecules (B7.1, ICAM-1, and LFA-3).
18537185Hepatocellular CarcinomaPromote immunityAd-CD40L transduction exerted CD40/CD40L interactions between DCs, increasing DC immunostimulation with up-regulation of CD80/CD86- and interleukin-12 (IL-12) expression.
16081691Chronic Lymphocytic LeukemiaPromote immunity (T cell function)We have investigated the ability of in vitro manipulated CLL cells, via hyperexpression of a triad of costimulatory molecules (B7-1, intercellular adhesion molecule 1 [ICAM-1], and leukocyte-function-associated antigen 3 [LFA-3], designated TRICOM), to stimulate effective antitumor T-cell responses.
15981208Renal Cell CarcinomaPromote immunityIn contrast, in a HLA Class I-matched situation, B7-2 is more effective in the induction of IFN-gamma and GM-CSF secretion than B7-1, but both B7 molecules induce T cell proliferation equally efficient.
15937544MelanomaPromote immunity (T cell function)The melanoma microenvironment may lead to local T cell tolerance in part through downregulation of costimulatory molecules, such as B7.1 (CD80).
21555531Lung Adenocarcinoma; Breast Carcinoma; Cutaneous Melanoma; Uveal MelanomaPromote immunityUsing seven cell lines representing four histologically distinct solid tumors (lung adenocarcinoma, mammary carcinoma, cutaneous melanoma, and uveal melanoma), we demonstrate that transfection of human tumor cells with the gene encoding the costimulatory molecule CD80 prevents PDL1-mediated immune suppression by tumor cells and restores T cell activation. Mechanistically, CD80 mediates its effects through its extracellular domain, which blocks the cell surface expression of PDL1 but does not prevent intracellular expression of PDL1 protein.
25085111lung carcinomaPromote immunityTherefore, CD11b+MC may compromise the ability of HBC to promote T cell activation in the setting of LM as a result of diminished expression of CD80
16920987pancreatic carcinomaPromote immunityMedium conditioned by human pancreatic carcinoma cells inhibited iMo-DC proliferation, expression of costimulatory molecules (CD80 and CD40) and of HLA-DR, and functional activity as assessed by MLR and IL-12p70 production. iMo-DC generated from pancreatic carcinoma patients in advanced stages of the disease similarly showed decreased levels of HLA-DR expression and reduced ability to stimulate MLR in response to CD40L and IFN-gamma.
16917008Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Promote immunityWe found that patient-derived MoDCs are phenotypically and functionally defective. Compared with their normal counterparts, patient-derived, mature MoDCs expressed significantly lower levels of CD1a, CD40, CD80, and HLA-DR and were poor at activating alloreactive T cells, presenting recall antigen, and activating autologous antigen- and myeloma-specific T cells.
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD80 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD80 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1140.653
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0090.985
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2030.595
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1050.809
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3120.723
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6420.593
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4780.394
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8670.316
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1640.853
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3050.622
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0980.914
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0030.99
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD80 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD80. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD80. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD80.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD80. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD80 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD80 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD80
NameCD80 molecule
Aliases B7.1; B7-1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 a ......
Chromosomal Location3q13.3-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD80 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD80.
ID Name Drug Type Targets #Targets
DB01281AbataceptBiotechCD80, CD862
DB04901GaliximabBiotechCD801
DB06681BelataceptBiotechCD80, CD862
DB11714DurvalumabBiotechCD274, CD802